PATIENTS WITH ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOSPITALIZATION STRUCTURE AND ANTITHROMBOTIC THERAPY (RECVASA AF-KURSK REGISTRY)

Study objective. To assess the peculiarities of hospitalization of patients with AF in combination with CHD in the departments of the general therapeutic profile of a multidisciplinary hospital, the frequency of complications of various forms of AF, to analyze anticoagulant (AC) and antiplatelet (AP) therapy in prehospital (PreH), hospital and post-hospital (PostH) stages of treatment based on the register. Material and methods. 502 patients were included in the prospective hospital registry RECVASA AF-Kursk, 480 of which with the diagnosis of AF in combination with ischemic heart disease were hospitalized in the therapeutical departments of Kursk Emergency Hospital during the period from 01.06.2013 to 31.05.2014. 2-3 years after the referral hospitalization, information about the drugs taken was collected after telephone or face-to-face contact with survived patients (n = 293), as well as their relatives, treating doctors. Results. The study included 261 women and 219 men, with an average age of 70.4 ± 10.3 years. The greatest number of patients with AF was treated in the departments of cardiology and therapy. In all departments, patients with a permanent AF prevailed, with the exception of cardiology, where the proportion of patients with persistent AF was the greatest. The share of stroke and MI was 39.4% and 29.8%, respectively. The cases of emergent hospitalizations recorded 56.8%, 28.6% of them — because of the AF. Among patients with different forms of AF, there were no differences in the frequency of emergent hospitalizations (p>0.05). The polyclinic directed 38% of patients, 41% of AF (p = 0.007). In all cases, the main cause of the hospitalization was cardiovascular disease (CVD). In patients with AF and IHD, prognostically significant AC therapy at the outpatient stage was assigned in 5.3%. By the time of discharge from hospital, the frequency of application of AC increased to 26.5% (p = 0.0001); Among patients with a permanent AF, AC are used significantly more often — in 30% of cases, in comparison with other forms of AF. At the PH stage, there remains a low share of AC (20%). At the same time in 20% of the PreH stage, 74.2% at the time of discharge and 64.5% of the cases at the PostH stage, instead of AC, AP were unreasonably prescribed. Conclusion. According to the prospective registry RECVASA AF-Kursk patients with AF in combination with IHD are hospitalized in the hospital, mainly because of CVD, half of them for emergent indications. Stroke and MI in this category of patients reaches a third of cases. There is a low frequency of prescribing ACat all stages of treatment (5.3% in PreH, 26.5% at discharge and 20.2% in PostH stages), unjustifiably replaced with AP therapy. At the hospital and PostH stages, significantly more frequent use of both AC and AP is observed in comparison with the PreH stage.

atrial fibrillation, ischemic heart disease, hospitalization structure, antithrombotic therapy, anticoagulants, antiplatelets, registry

1. Сулимов В.А., Напалков Д.А., Соколова А.А. и др. Антикоагулянтная терапия в реальной клинической практике: данные ретроспективного одномоментного исследования. Рациональная фармакотерапия в кардиологии. 2015; 11(2):116-123. Sulimov V.A., Napalkov D.A., Sokolova A.A. et al. Anticoagulant therapy in everyday clinical practice: data of the retrospective crosssectional study. Ration Pharmacother Cardiol. 2015; 11(2): 116-123 [in Russian].

2. Бокерия, Л.А., Ступаков И.Н., Самородская И.В. Результаты эпидемиологического исследования «Структура болезней системы кровообращения и потребность в отдельных видах специализированной лечебно-диагностической помощи среди взрослых пациентов, обратившихся за медицинской помощью в государственные медицинские учреждения». Грудная и сердечно-сосудистая хирургия. 2007; 5: 4–8. Bockeria L.A. Results of epidemiological study «The Pattern of Circulatory Diseases and a Need for Some Types of Specialized Medical and Diagnostic Aid Among Adult Patients Resorting to State Health Care Facilities for Medical Aid». Grudnaya and serdechno-sosudistaya chirurgia. 2007; 5: 4-8 [in Russian].

3. Гиляров М.Ю., Константинова Е.В. Фибрилляция предсердий как фактор риска ишемического инсульта. Сonsilium Medicum. 2015; 17(9): 16-19. Gilyarov M.Yu., Konstantinova E.V. Atrial fibrillation as a risk factor for ischemic stroke. Сonsilium Medicum. 2015; 17(9): 16-19 [in Russian].

4. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК, ВНОА, АССХ (2012). Российский кардиологический журнал. 2013; 4: 6-36. Diagnosis and treatment of atrial fibrillation. RSC/RSSA/RACVS guidelines. 2013; 4: 6-36 (Available at: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf) [in Russian].

5. Лукьянов М.М., Бойцов С.А., Якушин С.С. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии. 2014; 10(4): 366-377. Loukianov M.M., Boytsov S.A., Yakushin S.S. et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of «atrial fibrillation» in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Ration Pharmacother. Cardiol. 2014; 10(4): 366-377 [in Russian].

6. Марцевич С.Ю., Навасардян А.Р., Кутишенко Н.П. и др. Опыт изучения фибрилляции предсердий на базе регистра ПРОФИЛЬ. Кардиоваскулярная терапия и профилактика. 2014; 2: 35-39. Martsevich S.Y., Navasardyan A.R., Kutishenko N.P. et al. Studying atrial fibrillation on the basis of PROFILE registry. Cardiovascular Therapy and Prevention. 2014; 2: 35-39 [in Russian].

7. Бойцов С.А., Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лукьянов М.М. и др. Регистры в кардиологии. Основные правила проведения и реальные возможности. Кардиоваскулярная терапия и профилактика. 2013; 1: 4-9. Boytsov S.A., Martsevich S.Yu., Kutishenko N.P, Drozdova L.Yu., Lukyanov M.M. et al. Registers in cardiology: their principles, rules, and real-word potential. 2013; 1: 4-9 [in Russian].

8. Andersson T., Magnuson A., Bryngelsson I.L. et.al. All-cause mortality in 272, 186 patients hospitalized with incident atrial fibrillation 1995- 2008: a Swedish nationwide long-term case-control study. Euro Heart J. 2013; 34: 1061–1067.

9. AHA/ASA Guidelines for the Primary Prevention of Stroke. Stroke. 2014; 45: 3754-3832.

10. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016; 18(11): 1609-1678.

11. Chamberlain A.M., Redfield M.M., Alonso A., Weston S.A., Roger V.L. Atrial fibrillation and mortality in heart failure: a community study. Circ. Heart Fail. 2011; 4: 740-746. doi:10.1161/CIRCHEARTFAILURE.111.962688. 21920917

12. Chugh S.S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129(8): 837-847. doi: 10.1161/CIRCULATIONAHA.113.005119.

13. Gasparini M., Auricchio A., Metra M. et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrioventricular junction ablation in patients with permanent atrial fibrillation. Eur. Heart J. 2008; 29: 1644–1652.

14. Haim M., Hoshen M., Reges O. et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J. Am. Heart Assoc. 2015; 4(1): e001486. doi: 10.1161/JAHA.114.001486.

15. Lip G.Y, Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272.

16. Szwejkowski R., Rekhraj S., Morris D., Struthers A. and D. Atrial fibrillation in diabetes: A cause for concern? Journal of Diabetes Mellitus. 2012; 2: 378-385. doi: 10.4236/jdm.2012.24059 1

17. Rodríguez-Mañero M., Bertomeu-González V., Cordero A. et al. Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years. Rev. Port. Cardiol. 2013 Feb; 32(2): 103-109.

18. Saposnik G., Kapral M.K., Liu Y. et al. Investigators of the Registry of the Canadian Stroke NetworkStroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation 2011; 123: 739-749. doi:10.1161/CIRCULATIONAHA.110.983353. 21300951

19. Waldo A.L., Becker R.C., Tapson V.F., Colgan K.J. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J. Am. Coll. Cardiol. 2005; 46: 1729-1736.